Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P35367
UPID:
HRH1_HUMAN
Alternative names:
-
Alternative UPACC:
P35367; A8K047; Q6P9E5
Background:
The Histamine H1 receptor plays a pivotal role in mediating various physiological responses, including smooth muscle contraction, capillary permeability, and neurotransmission in the central nervous system. This receptor's involvement in both peripheral tissues and the central nervous system underscores its significance in human physiology.
Therapeutic significance:
Understanding the role of Histamine H1 receptor could open doors to potential therapeutic strategies. Its central role in mediating critical physiological processes presents an opportunity for targeted drug development, potentially addressing a range of conditions.